未控制的重度口服糖皮质激素依赖型哮喘患者中与强的松龙相关的2型生物标志物和细胞因子的变化：一项开放性干预研究
2019/08/28
摘要
44例未控制的重度口服糖皮质类固醇(OCS)依赖型哮喘患者，给予7天强的松龙(0.5 mg/kg)刺激，测量2型生物标志物和相关细胞因子(IL-5、IL-13)、肺功能和哮喘症状直到第88天。大剂量口服OCS降低血液中嗜酸性粒细胞的中位数为(-60细胞/µl;95% CI -140〜10)，骨膜蛋白(-8.4 ng/mL;-11.6〜-2.8)，FeNO (-19.0ppb;-28.5〜-4.0)， IL-5 (-0.17 pg/mL;-0.28〜-0.08)和IL-13 (-0.15 pg/mL;-0.27〜-0.03)。FEV1 (0.16 L; 0.05〜0.27)和哮喘控制问卷ACQ-7评分(0.3;0.0〜0.7)两项指标得到很小的改善。研究措施恢复到干预后1个月的水平。在使用2型生物标志物指导长期治疗前，1个月的时间足以挽救OCS。
Busby J, Holweg CTJ, Chai A, Bradding P, Cai F, Chaudhuri R, Mansur AH, Lordan JL, Matthews JG, Menzies-Gow A, Niven R, Staton T, Heaney LG.
Abstract
Type-2 biomarkers and related cytokines (IL-5, IL-13), lung function and asthma symptoms were measured in 44 poorly-controlled severe oral corticosteroid (OCS)-dependent asthmatics for up to 88 days after a 7-day prednisolone boost (0.5 mg/kg). High-dose OCS reduced median blood eosinophils (-60 cells/µl; 95% CI -140 to 10), periostin (-8.4 ng/mL; -11.6 to -2.8), FeNO (-19.0 ppb; -28.5 to -4.0), IL-5 (-0.17 pg/mL; -0.28 to -0.08) and IL-13 (-0.15 pg/mL; -0.27 to -0.03). There were small improvements in mean FEV1 (0.16 L; 0.05 to 0.27) and (Asthma Control Questionnaire) ACQ-7 score (0.3; 0.0 to 0.7). Study measures returned to baseline 1-month postintervention. Following rescue OCS, 1 month is sufficient before using type-2 biomarkers to guide long-term treatment.
44例未控制的重度口服糖皮质类固醇(OCS)依赖型哮喘患者，给予7天强的松龙(0.5 mg/kg)刺激，测量2型生物标志物和相关细胞因子(IL-5、IL-13)、肺功能和哮喘症状直到第88天。大剂量口服OCS降低血液中嗜酸性粒细胞的中位数为(-60细胞/µl;95% CI -140〜10)，骨膜蛋白(-8.4 ng/mL;-11.6〜-2.8)，FeNO (-19.0ppb;-28.5〜-4.0)， IL-5 (-0.17 pg/mL;-0.28〜-0.08)和IL-13 (-0.15 pg/mL;-0.27〜-0.03)。FEV1 (0.16 L; 0.05〜0.27)和哮喘控制问卷ACQ-7评分(0.3;0.0〜0.7)两项指标得到很小的改善。研究措施恢复到干预后1个月的水平。在使用2型生物标志物指导长期治疗前，1个月的时间足以挽救OCS。
(中日友好医院呼吸与危重症医学科 张清 摘译 林江涛 审校)
(Thorax. 2019 Aug;74(8):806-809. doi: 10.1136/thoraxjnl-2018-212709. Epub 2019 Apr 2.)
(Thorax. 2019 Aug;74(8):806-809. doi: 10.1136/thoraxjnl-2018-212709. Epub 2019 Apr 2.)
Change in type-2 biomarkers and related cytokines with prednisolone in uncontrolled severe oral corticosteroid dependent asthmatics an interventional open-label study
Busby J, Holweg CTJ, Chai A, Bradding P, Cai F, Chaudhuri R, Mansur AH, Lordan JL, Matthews JG, Menzies-Gow A, Niven R, Staton T, Heaney LG.
Abstract
Type-2 biomarkers and related cytokines (IL-5, IL-13), lung function and asthma symptoms were measured in 44 poorly-controlled severe oral corticosteroid (OCS)-dependent asthmatics for up to 88 days after a 7-day prednisolone boost (0.5 mg/kg). High-dose OCS reduced median blood eosinophils (-60 cells/µl; 95% CI -140 to 10), periostin (-8.4 ng/mL; -11.6 to -2.8), FeNO (-19.0 ppb; -28.5 to -4.0), IL-5 (-0.17 pg/mL; -0.28 to -0.08) and IL-13 (-0.15 pg/mL; -0.27 to -0.03). There were small improvements in mean FEV1 (0.16 L; 0.05 to 0.27) and (Asthma Control Questionnaire) ACQ-7 score (0.3; 0.0 to 0.7). Study measures returned to baseline 1-month postintervention. Following rescue OCS, 1 month is sufficient before using type-2 biomarkers to guide long-term treatment.
上一篇：
以流感收入院的哮喘患者全身及局部炎症表现特点
下一篇：
1个月至13岁哮喘患儿气道阻塞和支气管反应：一项前瞻性出生队列研究
